Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
The weekly transaction volume of DApps on the Solana chain reached $20.9 billion, a decrease of 30% compared to the previous week

The weekly transaction volume of DApps on the Solana chain reached $20.9 billion, a decrease of 30% compared to the previous week

Bitget2024/12/28 01:29

SOL's recent poor performance has raised concerns among traders about a potential further price decline. Solana ranks second in on-chain DApp trading volume with a weekly volume of $20.9 billion, but it performed the worst among the top 10 blockchains, dropping 30% over seven days. In contrast, Ethereum's on-chain trading volume fell by 15%, while Sui decreased by 8%. The Solana network's TVL reached its highest level in two years at 44 million SOL. According to DefiLlama data, the monthly growth of 16% was driven by platforms such as Binance Staked SOL, Jupiter, Drift, and Orca. On the downside, deposits for Jito, Sanctum, and MarginFi have declined. (Cointelegraph)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss